Trial | NCT00247663  Report issue

Official Title

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    letrozole ...

  • Study Participants

    17
- To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.
Study Started
Dec 31
1999
Primary Completion
Dec 31
2005
Last Update
Apr 19
2012
Estimate

Drug Letrozole

  • Other names: FEM345

Letrozole Experimental

Criteria 

Inclusion Criteria:

- Patients which participated in double blind study

Exclusion Criteria:

Patients with intolerable toxicity.
Patients which confirmed progressive disease during double blind study.
Patients which have received concurrent anti-cancer therapy during double blind study.
No Results Posted